Intellectual Property partner Kevin O'Connor was recently interviewed by BioPharma-Reporter for the article, "Amgen v Sanofi Ruling: It Is Time to Kiss Goodbye to Broad, Functional Patent Claims for Antibodies."  In the article, Kevin discusses a U.S. court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims, which has biotech manufacturers concerned about how to preserve their IP.

Click here to read the interview.